Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N7JZ
|
|||
| Former ID |
DIB012408
|
|||
| Drug Name |
SAND-26
|
|||
| Synonyms |
Begedina; CD26-targeting antibody (autoimmunity), ADIENNE
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 3 | [1], [2] | |
| Company |
ADIENNE Pharma & Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | . | [3] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8691). | |||
| REF 2 | ClinicalTrials.gov (NCT02411084) Study of BEGEDINA vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Siesonline. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.